Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chromium picolinate shows promise for teen skin condition linked to insulin resistance

NCT ID NCT07371169

Disease control Sponsor: Uruk University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether taking chromium picolinate daily for 24 weeks could reduce the severity of acanthosis nigricans (dark, thick skin patches) and improve insulin resistance in adolescents aged 12 to 18. Researchers compared the supplement to a placebo in 90 participants. The goal was to see if a simple supplement could help manage these conditions without major side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
chromium picolinate
What this could lead to
If it works, this could point toward a simple supplement to help manage skin changes and insulin resistance in teens.
What could go wrong
This is a small, completed trial with 90 participants, so results may not apply broadly. Chromium supplements can have side effects and may not be effective for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Started

Jan 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adolescent patients of both sexes, aged 12 to 18 years. * Clinically diagnosed with acanthosis nigricans. * Present Insulin resistance, defined as Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) ≥ 2.5. * Willing to participate in the study, with written informed consent provided by both the patient and guardian. Exclusion Criteria: * Diagnosis of type 1 or type 2 diabetes mellitus. * Known hypersensitivity to chromium or any of the capsule excipients. * Use of insulin-sensitizing medications (e.g., metformin, thiazolidinediones) within 3 months before screening. * Use of systemic corticosteroids or other medications known to affect glucose metabolism within 3 months before screening. * Significant renal disease (estimated glomerular filtration rate \< 60 mL/min/1.73 m²) or liver disease (alanine aminotransferase or aspartate aminotransferase \> 2.5 times the upper limit of normal). * Pregnancy or lactation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acanthosis nigricans are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acanthosis nigricans Insulin Resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acanthosis nigricans Insulin resistance

Contacts and locations

Locations

  • Baghdad Medical City / Children Welfare Teaching Hospital / Department of Endocrinology

    Baghdad, Baghdad Governorate, 10045, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.